Здоровье легких – еще один повод бросить курить

Здоровье легких – еще один повод бросить курить

Отказ от курения – наиболее эффективный способ предотвращения заболеваний легких и снижения риска и прогноза хронических и острых инфекций дыхательных путей




 

Служба Медицинской Информации: [email protected]. Доступ к информации о рецептурных препаратах Pfizer в России: www.pfizermedinfo.ru
Copyright 2020 Пфайзер Россия. Все права защищены. Информация предназначена только для специалистов здравоохранения Российской Федерации.

Phizer OOO "Пфайзер Инновации"
123112, Москва, Пресненская наб., д.10, БЦ "Башня на Набережной" (блок С)
Тел.: +7 495 287 50 00. Факс: +7 495 287 53 00

PP-CHM-RUS-0531 16.11.2020

 

Источники:

1.Chronic obstructive pulmonary disease (COPD) – WHO Fact Sheet. November 2016. Available at: http://www.who.int/mediacentre/factsheets/fs315/en/ [Accessed Oct 16th 2020]

2.Eisner M.D., Anthonisen N., Coultas D. et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 693–718.

3. Lamprecht B, McBurnie MA, Vollmer WM, et al., BOLD Collaborative Research Group: COPD in never smokers: results form the population-based burden of obstructive lung disease study. Chest 2011; 139: 752–763.

4.Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165–1185.

5. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015 Aug;3(8):631-9. doi: 10.1016/S2213-2600(15)00241-6. Epub 2015 Jul 22. PMID: 26208998.

6. TemitayoOrisasami I, Ojo O. Evaluating the effectiveness of smoking cessation in the management of COPD. Br J Nurs. 2016 Jul 28;25(14):786-91. doi: 10.12968/bjon.2016.25.14.786. PMID: 27467642.

7.Рак легкого. Клинические рекомендации. // Минздрав РФ URL: https://nop2030.ru/files/2019/08/025.pdf (дата обращения 17.10.2020)

8. По данным нового доклада ВОЗ, 90% случаев рака легких можно предотвратить с помощью прекращения употребления табака. // ВОЗ URL:  https://www.euro.who.int/ru/health-topics/disease-prevention/tobacco/news/news/2019/5/90-of-lung-cancers-can-be-avoided-by-eliminating-tobacco-use,-new-who-report-reveals (дата обращения 17.10.2020)

9. У меня рак легких — есть ли смысл бросать курить? // GlobalLungCancerCoalition URL: http://www.lungcancercoalition.org/uploads/docs/GLCC_SmokingCessation2017_RU.pdf (дата обращения 17.10.2020)

10. Титова О. Н., Куликов В. Д., Суховская О. А. Табакокурение и грипп (обзор) //Медицинский Альянс. – 2020. – №. 1.;

11.Lawrence H. et al. Cigarette smoking and the occurrence of influenza–Systematic review //Journal of Infection. – 2019. – Т. 79. – №. 5. – С. 401-406.;

12. Godoy P. et al. Smoking may increase the risk of influenza hospitalization and reduce influenza vaccine effectiveness in the elderly //The European Journal of Public Health. – 2018. – Т. 28. – №. 1. – С. 150-155.

13. Wong C. M. et al. Cigarette smoking as a risk factor for influenza?associated mortality: evidence from an elderly cohort //Influenza and other respiratory viruses. – 2013. – Т. 7. – №. 4. – С. 531-539.;

14. Nuorti J. P. et al. Cigarette smoking and invasive pneumococcal disease //New England Journal of Medicine. – 2000. – Т. 342. – №. 10. – С. 681-689.

15.Fischer M. et al. Tobacco smoke as a risk factor for meningococcal disease //The Pediatric infectious disease journal. – 1997. – Т. 16. – №. 10. – С. 979-983.

16. Заявление ВОЗ: Табакокурение и COVID-19. // ВОЗ URL:
https://www.who.int/ru/news-room/detail/11-05-2020-who-statement-tobacco-use-and-covid-19 (дата обращения 17.10.2020)

17. Liu W, Tao ZW, Lei W, Ming-Li Y, Kui L, Ling Z, Shuang W, Yan D, Jing L, Liu HG, Ming Y. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chinese medical journal. 2020 Mar 6

18. Coronavirus and lungs: How do smoking, vaping, air pollution affect respiratory illnesses? // Cleveland.com
URL: https://www.cleveland.com/news/2020/03/coronavirus-and-lungs-how-do-smoking-vaping-air-pollution-affect-respiratory-illnesses.html (дата обращения 17.10.2020)

19.  Wang, J.; Luo, Q.; Chen, R.; Chen, T.; Li, J. Susceptibility Analysis of COVID-19 in Smokers Based on ACE2. Preprints 2020, 2020030078 (doi: 10.20944/preprints202003.0078.v1)

20. Клинические рекомендации "Хроническая обструктивная болезнь легких" Минздрав РФ URL: http://www.consultant.ru/document/cons_doc_LAW_324821/ (дата обращения 17.10.2020)

21. Global Strategy for the Diagnosis, Management and Prevention of COPD [2018 Report] URL: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf (датаобращения 17.10.2020)

22. Vadasz 2009. Vadasz I. The first Hungarian experiences with varenicline to support smoking cessation. MedicinaThoracalis LXII.1. February 2009: 1-9

23. Kotz D, Viechtbauer W, Simpson CR, van Schayck OCP, West R, Sheikh A. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease. Thorax. 2017 Oct;72(10):905-911. doi: 10.1136/thoraxjnl-2017-210067. Epub 2017 May 4. PMID: 28473506.

24. Cahill K et al. The Cochrane Collaboration; The Cochrane Library 2008, Issue 3. Art. No.: CD006103.  DOI: 10.1002/14651858.CD006103.pub3.

25. Инструкция по медицинскому применению лекарственного препарата для медицинского применения Чампикс® РН ЛСР-006439/08

26. Rollema H. et al. Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation //Trends in pharmacological sciences. – 2007. – Т. 28. – №. 7. – С. 316-325.

27. Gonzales D. etal. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial //Jama. – 2006. – Т. 296. – №. 1. – С. 47-55.

28. Vadasz I. The first Hungarian experiences with varenicline to support smoking cessation. MedicinaThoracalis LXII.1. February 2009: 1-9

29. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Tashkin DP1 ,Rennard S2 , Hays JT3 , Ma W4 , Lawrence D5 , Lee TC5 . Chest 2011

30. Rigotti N. A. et al. Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease//Circulation. – 2010. – Т. 121. – №. 2. – С. 221-229;

31. Prochaska JJ, Hilton JF Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 20 1 2 May 4; 344: e2856. doi: 10. 1136/bmj.e2856.

32. Sterling LH, Windle SB, et al. Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2016 Feb 22;5(2).

33. Eisenberg M. J. et al. Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome //Circulation. – 2016. – Т. 133. – №. 1. – С. 21-30.

Вход на сайт